复发/难治性多发性骨髓瘤(既往1-3线治疗)的真实世界治疗模式与结局:Flatiron数据库
基于Flatiron健康数据库2016年1月至2022年4月12 767例多发性骨髓瘤患者,筛选出1455例蛋白酶体抑制剂暴露且来那度胺难治、既往1-3线治疗的患者。最常见后续治疗为三药联合(41.6%),最常见方案为达雷妥尤单抗/泊马度胺/地塞米松(13.2%)。中位真实世界无进展生存期(RW-PFS)6.5个月,中位总生存期(OS)44.4个月;1、2、3线既往治疗患者RW-PFS相似。
要点
- 来那度胺难治性多发性骨髓瘤患者中位RW-PFS仅6.5个月,中位OS 44.4个月。
- 最常见后续治疗为三药联合(41.6%),达雷妥尤单抗/泊马度胺/地塞米松最常见(13.2%)。
- 既往1线治疗者从2线到5线累积脱落率85%,其中25%死亡、60%未再治疗。
核心结论
- 来那度胺难治且既往接受1-3线治疗的多发性骨髓瘤患者结局差,在可用治疗中快速进展,凸显在疾病早期、患者因脱落而流失之前需要更有效治疗。
研究设计与样本
- 基于Flatiron健康数据库2016年1月至2022年4月12 767例多发性骨髓瘤患者的真实世界研究,筛选出1455例蛋白酶体抑制剂暴露、来那度胺难治且既往接受1-3线治疗的患者。
主要发现
- 最常见后续治疗为三药联合(41.6%),最常见方案为达雷妥尤单抗/泊马度胺/地塞米松(13.2%)。
- 中位真实世界无进展生存期(RW-PFS)为6.5个月,中位总生存期(OS)为44.4个月。
- 既往1、2、3线治疗患者的RW-PFS相似。
- 国际分期系统III期、美国东部肿瘤协作组体能状态1、血红蛋白<12 g/dL、高危细胞遗传学及基线时抗CD38抗体难治与更差RW-PFS和OS相关。
- 接受美国国家综合癌症网络优先治疗及2020年后治疗的患者结局相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the context of multiple myeloma (MM), early use of the immunomodulatory drug lenalidomide has led to an increased population of patients with lenalidomide-refractory MM in early-line settings, but their outcomes are not well characterized. Herein, we report treatment patterns, survival outcomes, prognostic variables, and attrition rates for patients with proteasome inhibitor-exposed, lenalidomide-refractory MM, treated with 1 to 3 prior lines of therapy (LOT). From 12 767 patients with MM in the Flatiron Health database between January 2016 and April 2022, 1455 met the inclusion criteria. The most common subsequent treatments were triplet combinations (41.6% of patients); daratumumab/pomalidomide/dexamethasone was the most common treatment regimen (13.2%). Median real-world progression-free survival (RW-PFS) and overall survival (OS) were 6.5 months and 44.4 months, respectively. RW-PFS was similar in patients with 1, 2, or 3 prior LOT. International Staging System stage III, Eastern Cooperative Oncology Group performance status of 1, hemoglobin <12 g/dL, high-risk cytogenetics, and refractoriness to anti-CD38 antibody at baseline were associated with worse RW-PFS and OS. Outcomes remained similar for patients who received National Comprehensive Cancer Network-preferred treatments and those who received treatments after 2020. In 561 patients with 1 prior LOT at inclusion, the cumulative attrition rate from LOT 2 to 5 was 85%, which included 25% patients who died and 60% with no further treatment. Patients with lenalidomide-refractory MM who have received 1 to 3 prior LOT have poor outcomes and progress rapidly through available therapies, highlighting the need for more effective treatments early in the disease course, before patients are lost to attrition.
引用
- Dhakal B, Einsele H, Schecter JM, et al. Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database. Blood Adv. 2024. PMID: 39110988. doi:10.1182/bloodadvances.2024012640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。